echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > In 2022, the "break" of innovative pharmaceutical companies will continue!

    In 2022, the "break" of innovative pharmaceutical companies will continue!

    • Last Update: 2022-04-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    In recent years, under the background of domestic encouragement and support for pharmaceutical innovation and R&D, the development of the innovative drug industry has entered the "fast lane", and capital is also chasing it
    .
    However, the breakout of innovative drug companies seems to have become the norm
    .
    In 2020, Simcere, Harbin Pharmaceutical, and WuXi Junuo fell below their issue prices on the first day of listing; among the new stocks that landed on the Sci-tech Innovation Board in 2021, many such as Kintor and BeiGene listed on the day of listing.
    Medium break
    .
    Entering 2022, the "breakthrough" of innovative pharmaceutical companies will continue
    .
    In January, Asieris Pharmaceuticals broke through at the opening of the market and became the first biopharmaceutical stock on the Science and Technology Innovation Board this year
    .
    Subsequently, Maiwei Bio was listed on January 18, 2022, but it also broke at the opening and fell by more than 8%
    .
    As of the close of the day, Maiwei Bio closed at 24.
    5 yuan, down 29.
    6%
    .
    Regarding the trend of new pharmaceutical stocks breaking at the opening, some market participants believe that the main reason for the breaking of new stocks is that the price is too high.
    The revision of the new stock pricing rules has pushed up the issuance price-earnings ratio.
    The attitude of the secondary market towards high-priced technology stocks tends to be cautious.
    Makes the new shares prone to break
    .
    In addition, there are also some companies that have suffered serious breakouts because the company's fundamentals are not optimistic, and the performance performance is not satisfactory
    .
    A research team pointed out that since the third quarter of 2021, the pharmaceutical sector has experienced a downturn, and due to the impact of the domestic centralized procurement policy, the epidemic and other factors, the performance of many pharmaceutical companies has been impacted, and the market value of many leading pharmaceutical companies has also undergone major adjustments.

    .
    On the whole, the valuation logic system of pharmaceutical companies has changed, which has also led to a breakdown of new pharmaceutical stocks and a decline in stock prices
    .
    In addition, some investors believe that there are several reasons: First, the timing is not good.
    Since the stock price of Dizhe Pharmaceuticals has fallen since the opening of the market, the low market sentiment has affected investors; second, the current secondary market includes investors, The pricing of 18A and similar companies is still unclear, and the commercialization capability needs time to be verified, which also makes the entire market into a downturn.
    How to balance the company's hard power and commercialization capability is also a major difficulty in the current market
    .
    It is true that the opening of the Science and Technology Innovation Board has given many unprofitable pharmaceutical companies the opportunity to raise funds and go public.

    .
    However, we must also see that the research and development of domestic innovative drugs is hot, and the competition for popular targets is becoming more and more fierce.
    Many pharmaceutical companies are getting together to develop monoclonal antibodies, CAR-T and gene therapy
    .
    Taking PD-L1 monoclonal antibody as an example, the track has become more and more "involution" 
    .
    At present, there are 12 PD-1/PD-L1 models on the market in China, including 6 domestic PD-1s, 2 domestic PD-L1s, 2 imported PD-1s and 2 imported PD-L1s
    .
    There are 6 models that are in the stage of application for listing, including Zhaoke Pharmaceutical's Shoukalimumab, Kelun Pharmaceutical's Tetlimumab and Hengrui Medicine's adebelimumab
    .
    In addition, there are more than 100 drugs in different clinical stages
    .
    Taking CAR-T as an example, according to statistics, the number of domestic clinical trials of CAR-T cell therapy has reached 335 in 2020, a tenfold increase in five years
    .
    Among them, CAR-T clinical trials targeting CD19 accounted for more than 40%
    .
    What needs to be seen clearly is that many pharmaceutical companies with products under development are not yet profitable, and most companies choose to develop Me-too innovative drugs instead of difficult first-in-class innovative drugs.
    The new regulations encourage doing so.
    Innovative drugs rather than pseudo-innovations are enough to show that the policy side is inclined to innovative products with core strengths
    .
    Therefore, for investors, whether such pharmaceutical companies have core strengths and how to achieve commercialization are unavoidable topics
    .
    Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
    .
    window.
    _bd_share_config={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"32"},"share":{},"image":{"viewList":["weixin","sqq","qzone","tsina","tqq"," tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:", "viewSize":"24"},"selectShare":{"bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu", "tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}};with(document)0[(getElementsByTagName('head ')[0]||body).
    appendChild(createElement('script')).
    src='http://bdimg.
    share.
    baidu.
    com/static/api/js/share.
    js?v=89860593.
    js ?cdnversion='+~(-new Date()/36e5)]; Keywords: In 2022, innovative pharmaceutical companies will continue to "break"! , Innovative pharmaceutical companies, break the next article: A number of innovative pharmaceutical companies have performed well in commercialization, and sales revenue has grown strongly! Previous: Pay attention to the fast-growing sector in the first quarterly report.
    Yesterday, many pharmaceutical companies disclosed that their performance increased by more than 1 times.
    js?cdnversion='+~(-new Date()/36e5)]; Key words: In 2022, the "break" of innovative pharmaceutical companies will continue! , Innovative pharmaceutical companies, break the next article: A number of innovative pharmaceutical companies have performed well in commercialization, and sales revenue has grown strongly! Previous: Pay attention to the fast-growing sector in the first quarterly report.
    Yesterday, many pharmaceutical companies disclosed that their performance increased by more than 1 times.
    js?cdnversion='+~(-new Date()/36e5)]; Key words: In 2022, the "break" of innovative pharmaceutical companies will continue! , Innovative pharmaceutical companies, break the next article: A number of innovative pharmaceutical companies have performed well in commercialization, and sales revenue has grown strongly! Previous: Pay attention to the fast-growing sector in the first quarterly report.
    Yesterday, many pharmaceutical companies disclosed that their performance increased by more than 1 times.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.